Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.
Chan Cheah, MBBS, clinical professor, University of Western Australia (WA), consultant hematologist, lymphoma lead, fellowship program director, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine WA, Linear Clinical Research and Hollywood Private Hospital, founder, Blood Cancer Research WA, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab (TG-1101) and umbralisib (Ukoniq; U2) in chronic lymphocytic leukemia (CLL).
During the 2021 International Workshop on CLL, findings from an ongoing phase 1 trial (NCT03671590) evaluating TG-1701, a selective BTK inhibitor, as monotherapy and in combination with U2 in patients with CLL were presented virtually. Single-agent TG-1701 demonstrated an objective response rate (ORR) of 83%. Additionally, the 3 patients who received the triplet regimen achieved an objective response, Cheah explains.
By disease-specific cohort, the ORR was 95% in patients who received 200 mg of TG-1701 and 100% in patients who received 300 mg of TG-1701 at a median follow-up of 19 months and 12 months, respectively. Ultimately, these findings indicate that TG-1701 is an effective BTK inhibitor alone or in combination with U2 in CLL, Cheah concludes.